Pharma & Bio
Technology
NATURECELL CO.,LTD.: JointStem Controversy Reignites Following Shareholder Complaint… Key Issues Moving Forward
(Graphic: Generative AI)
NATURECELL CO.,LTD.(007390) The controversy has reignited as shareholders of NatureCell have refiled charges against officials from the Ministry of Food and Drug Safety (M…
Technology
‘Original PDRN’ Rejuran Enters the PDRN Market… Why It Chose Raphas Co., Ltd. as a Partner
Polydeoxyribonucleotide (PDRN) and polynucleotide (PN), which were primarily used in dermatological injection treatments, are rapidly expanding into the cosmetics market. Product forms have diversifie…
Lifestyle
Investor Sentiment Rebounds: SillaJen, Bioneer, and Vivozon Pharma Surge on Tangible R&D and Financial Milestones [K-Bio Pulse]
Investor sentiment across South Korea’s pharmaceutical and biotechnology sectors is staging a robust recovery. Moving past the speculative momentum of the past, strong institutional and retail buying …
Lifestyle
Is Investor Sentiment Returning? SillaJen, Inc., BIONEER CORPORATION, and VIVOZON PHARMACEUTICAL—Companies with Proven Earnings and Development Achievements—Rise [Bio Market Watch]
Investor sentiment is recovering in the domestic pharmaceutical and biotech stock market. Unlike in the past, when sentiment relied on vague expectations, strong buying interest is now flowing primari…
Technology
Samyang Biopharm Hits Daily Price Limit as Moderna-MSD Cancer Vaccine Data Spark an mRNA Rally [K-Bio Pulse]
On August 20, South Korean pharmaceutical and biotech stocks related to messenger RNA (mRNA) cancer vaccines attracted significant investor attention after Moderna and Merck & Co. reported positive Ph…
Technology
Investors Scramble to Find Beneficiaries of Moderna and MSD’s Phase 3 Cancer Vaccine Trial… SAMYANG BIOPHARM CORPORATION Hits Daily Price Limit [Bio Spotlight]
(Graphic: Generative AI)
On the 20th, attention in the domestic pharmaceutical and biotech market was effectively focused on stocks related to messenger RNA (mRNA) cancer vaccines. Following news …
Technology
Could a Change in Indications Be a Blessing in Disguise?… What AprilBio Co.,Ltd. Needs to Do for 'APB-A1' to Make a Comeback
AprilBio Co.,Ltd.(397030)Since “APB-A1” (Lu AG22515), which was licensed to Lundbeck, failed to demonstrate the expected clinical efficacy in thyroid-associated ophthalmopathy (TED), the company is no…
Technology
Cancer Vaccine That Distributes ‘Wanted Posters’ for Cancer Cells and Builds an ‘Army of T Cells’… Moderna’s Success Is Changing the Game in Cancer Treatment
Immune cells that have memorized the “face” of cancer cells circulate throughout the body to track down any remaining cancer cells after surgery. The “cancer vaccine” whose potential was demonstrated …
Lifestyle
[K-Bio M&A Analysis] Lee Seung-kyu, Vice Chairman of the Korea Bio Association: “Opportunities for K-Bio Too… The Key Is Data” (Part 4)
“The fact that global Big Pharma companies are actively pursuing M&A presents an opportunity for K-Bio as well. Since global Big Pharma companies focus heavily on ‘data’ to rapidly commercialize their…
Technology
[Analysis of K-Bio M&A] K-Bio Through the Eyes of Experts: What Is the Formula for Successful M&A? (Part 3)
While mergers and acquisitions (M&A) have established themselves as a core growth strategy for securing new drug pipelines and technologies in the global pharmaceutical and biotech industries, it is d…